Updates in the Diagnosis and Management of Chronic Lymphocytic Leukemia: Strategies for Addressing Disparities in Patient Care and Outcomes

CME: 1.0

Target Audience

This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview

Advances in chronic lymphocytic leukemia (CLL) testing and therapy have redefined the standard of care in recent years, prompting updates to current guideline recommendations. At the same time, findings from ongoing clinical trials continue to inform treatment options and decisions for patients with CLL. In this activity, expert faculty will review the role of prognostic and predictive molecular biomarkers in CLL and novel approaches to treatment in the frontline and relapsed/refractory settings. Strategies for recognizing and managing adverse effects and reducing disparities in care in rural and underserved populations will also be discussed.

This enduring activity is a recorded session from Oncology Congress that took place on September 24, 2022.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Integrate advances in CLL testing to help diagnose, predict prognosis, and select personalized treatment for patients from rural and underserved communities
  • Apply current guideline recommendations and clinical trial data to personalize treatment of CLL in both the frontline and relapsed/refractory settings for patients from rural and underserved communities
  • Develop approaches to address CLL treatment adherence and adverse event monitoring and management, considering the unique challenges for rural and underserved settings

Post a comment to this article